Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
NCT03479268 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2026-04-27
Summary
This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or has stopped responding to other treatments. Pevonedistat and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions
- B-Cell Prolymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Diffuse Large B-Cell Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Recurrent Non-Hodgkin Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Diffuse Large B-Cell Lymphoma
- Refractory Follicular Lymphoma
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Non-Hodgkin Lymphoma
- Refractory Small Lymphocytic Lymphoma
- Richter Syndrome
Interventions
- DRUG
-
Given PO
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
- DRUG
-
Pevonedistat
Given IV
- OTHER
-
Pharmacokinetic Study
Correlative studies
- OTHER
-
Pharmacological Study
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
City of Hope Medical Center
lead OTHER
Principal Investigators
-
Alexey Danilov · City of Hope Medical Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-04-27
- Primary Completion
- 2026-11-05
- Completion
- 2026-11-05
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma
NCT01415765 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
NCT03484819 ·Status: COMPLETED ·Phase: PHASE2
-
PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma
NCT00354185 ·Status: TERMINATED ·Phase: PHASE1
-
Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NHL
NCT03349281 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
NCT03240211 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00003245 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
NCT06561074 ·Status: RECRUITING ·Phase: PHASE2
-
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
NCT03011814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
NCT02109224 ·Status: TERMINATED ·Phase: PHASE1
-
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT03704714 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT03518112 ·Status: TERMINATED ·Phase: PHASE2
-
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
NCT02159755 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
NCT02662296 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
NCT03645395 ·Status: TERMINATED ·Phase: PHASE2
-
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
NCT02213913 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders
NCT00052572 ·Status: COMPLETED ·Phase: PHASE2
-
UCN-01 and Fludarabine in Treating Patients With Recurrent or Refractory Lymphoma or Leukemia
NCT00019838 ·Status: COMPLETED ·Phase: PHASE1
-
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00348985 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
NCT02684292 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
NCT03278782 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
NCT00074282 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
NCT02568553 ·Status: COMPLETED ·Phase: PHASE1
-
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00109824 ·Status: COMPLETED ·Phase: PHASE1
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494 ·Status: COMPLETED ·Phase: PHASE2
-
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
NCT03409432 ·Status: COMPLETED ·Phase: PHASE2